(NAMs), to reduce, refine or replace vertebrate animal testing and provide information of equivalent or better scientific quality and relevance for assessing risks of injury to health or the environment.

ADDRESSES: The docket for this action, identified by docket identification (ID) number EPA-HQ-OPPT-2023-0627, is available online at <a href="http://www.regulations.gov">http://www.regulations.gov</a>. Additional instructions for visiting the docket, along with more information about dockets generally, is available at <a href="https://www.epa.gov/dockets">https://www.epa.gov/dockets</a>.

FOR FURTHER INFORMATION CONTACT: For technical information contact: Renee Beardslee, New Chemical Division (7405M), Office of Pollution Prevention and Toxics, Environmental Protection Agency, 1200 Pennsylvania Ave. NW, Washington, DC 20460–0001: telephone number: (202) 564–8787; email address: beardslee.renee@epa.gov.

For general information contact: The TSCA-Hotline, ABVI-Goodwill, 422 South Clinton Ave., Rochester, NY 14620; telephone number: (202) 554–1404; email address: TSCA-Hotline@epa.gov.

#### SUPPLEMENTARY INFORMATION:

#### I. Does this action apply to me?

This action is directed to the public in general. This notice may be of specific interest to persons who are or may be interested in risk assessments of new chemical substances under TSCA (e.g., submitters of TSCA 5 notices, industry, non-governmental organizations (NGOs), and academia). Since other entities may also be interested, the Agency has not attempted to describe all the specific entities that may be affected by this action.

#### II. What action is the Agency taking?

EPA is announcing the availability of a new decision framework for use by the New Chemicals Division (NCD) of the Office of Pollution Prevention and Toxics (OPPT) for identification of eye irritation or corrosion hazards for new chemical substances based on prioritization of reproducible, human-relevant data. The document supports EPA's efforts to develop NAMs that do not require vertebrate animal testing and furthers the agency's commitment to reduce and replace the use of vertebrate animals in the testing of chemical substances and mixtures.

TSCA section 4(h)(2)(A) directs EPA to "promote the development and implementation of alternative test methods and strategies to reduce, refine, or replace vertebrate animal testing and

provide information of equivalent or better scientific quality and relevance for assessing risks of injury to health or the environment."

To incorporate alternative test methods and strategies, or NAMs, data for eye irritation and corrosion hazard identification into the new chemicals program risk assessment process, NCD developed a framework for new chemical risk assessments that prioritizes reproducible, human-relevant in vitro data. The Framework is based upon existing peer-reviewed literature, accepted Organization for Economic Cooperation and Development (OECD) test guidelines, and other existing accepted risk assessment approaches.

NCD is responsible for conducting risk assessments for new chemical substances submitted under TSCA section 5 authority. NCD expects multiple benefits from the incorporation of this proposed Framework in its assessment including: (1) progress towards fulfilling TSCA section 4(h)(2) statutory requirements; (2) transparency for stakeholders regarding EPA's process of hazard identification of eye irritation and corrosion for new chemical submissions; (3) clear scientific rationale for identification of eye irritation and corrosion hazards for human health assessors leading to improved consistency across final new chemical risk assessments; and (4) use of the most reproducible, humanrelevant scientific data for decisionmaking.

# III. Does this Framework impose binding requirements?

This document is not binding on the Agency or any outside parties, and the Agency may depart from it where circumstances warrant and without prior notice. While EPA has made every effort to ensure the accuracy of the discussion in the Framework, the obligations of EPA and the regulated community are determined by statutes, regulations, or other legally binding documents. In the event of a conflict between the discussion in the Framework document and any statute, regulation, or other legally binding document, the Framework document will not be controlling.

# IV. Is this Framework subject to the Paperwork Reduction Act (PRA)?

This action does not contain any new or revised information collections or burden subject to additional OMB approval under the PRA, 44 U.S.C. 3501 *et seq.* Burden is defined in 5 CFR 1320.3(b). Information collection activities contained in the TSCA new

chemicals program are already approved by OMB under the PRA and are assigned OMB Control No. 2070–0038 (EPA ICR No. 1188.14).

Authority: 15 U.S.C. 2604 et seq.

Dated: January 3, 2024.

#### Michal Freedhoff,

Assistant Administrator, Office of Chemical Safety and Pollution Prevention.

[FR Doc. 2024–00169 Filed 1–8–24; 8:45 am]

BILLING CODE P

# FEDERAL DEPOSIT INSURANCE CORPORATION

### **Sunshine Act Meetings**

TIME AND DATE: 9:30 a.m. on Friday, January 5, 2024.

**PLACE:** The meeting was held via video conference on the internet.

STATUS: Closed.

MATTERS TO BE CONSIDERED: The Special Review Committee of the Federal Deposit Insurance Corporation met to consider matters related to the Corporation's corporate activities within its authority to act on behalf of the Federal Deposit Insurance Corporation. In calling the meeting, the Special Review Committee determined, by the unanimous vote of Director Jonathan P. McKernan and Director Michael J. Hsu (Acting Comptroller of the Currency), that Corporation business required its consideration of the matters which were to be the subject of this meeting on less than seven days' notice to the public; that no earlier notice of the meeting was practicable; that the public interest did not require consideration of the matters in a meeting open to public observation; and that the matters could be considered in a closed meeting by authority of subsections (c)(2) and (c)(4) of the "Government in the Sunshine Act" (5 U.S.C. 552b(c)(2) and (c)(4)).

#### CONTACT PERSON FOR MORE INFORMATION:

Requests for further information concerning the meeting may be directed to Debra A. Decker, Executive Secretary of the Corporation, at 202–898–8748.

Dated: January 5, 2024.

Federal Deposit Insurance Corporation.

#### James P. Sheesley,

Assistant Executive Secretary.

[FR Doc. 2024–00333 Filed 1–5–24; 4:15 pm]

BILLING CODE 6714-01-P

### **FEDERAL RESERVE SYSTEM**

## Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval,

pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at https://www.federalreserve.gov/foia/ request.htm. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than February 7, 2024.

A. Federal Reserve Bank of Atlanta (Erien O. Terry, Assistant Vice President) 1000 Peachtree Street NE, Atlanta, Georgia 30309; Comments can also be sent electronically to Applications.Comments@atl.frb.org]:

1. Eureka Investor Group, Inc., Birmingham, Alabama; to become a bank holding company by acquiring Eureka Homestead Bancorp, Inc., a savings and loan holding company, and thereby indirectly acquire Eureka Homestead, a savings association subsidiary, both of Metairie, Louisiana. In addition, Eureka Homestead Bancorp, Inc. will convert from a savings and loan holding company to a bank holding company in connection with Eureka Homestead's conversion from a savings association to a national bank.

Board of Governors of the Federal Reserve System.

#### Michele Taylor Fennell,

Deputy Associate Secretary of the Board. [FR Doc. 2024–00166 Filed 1–8–24; 8:45 am]

BILLING CODE P

## GOVERNMENT ACCOUNTABILITY OFFICE

#### Request for Medicare Payment Advisory Commission (MedPAC) Nominations

**AGENCY:** U.S. Government Accountability Office.

**ACTION:** Request for letters of nomination and resumes.

SUMMARY: The Balanced Budget Act of 1997 established the Medicare Payment Advisory Commission (MedPAC) and gave the Comptroller General responsibility for appointing its members. The U.S. Government Accountability Office (GAO) is now accepting nominations for MedPAC appointments that will be effective in May 2024. Nominations should be sent to the email address listed below. Acknowledgement of receipt will be provided within a week of submission.

**DATES:** Letters of nomination and resumes should be submitted no later than February 9, 2024, to ensure adequate opportunity for review and consideration of nominees prior to appointment.

ADDRESSES: Submit letters of nomination and resumes to MedPACappointments@gao.gov.

#### FOR FURTHER INFORMATION CONTACT:

Gregory Giusto at (202) 512–8268 or *giustog@gao.gov* if you do not receive an acknowledgement or need additional information. For general information, contact GAO's Office of Public Affairs at (202) 512–4800.

Authority: 42 U.S.C. 1395b-6.

#### Gene L. Dodaro,

Comptroller General of the United States. [FR Doc. 2024–00181 Filed 1–8–24; 8:45 am]

BILLING CODE 1610-02-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

## Centers for Disease Control and Prevention

#### **Notice of Closed Meeting**

Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential

trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)– RFA–PS–24–040, Understanding Infant Feeding Preferences, Practices, and Outcomes for Mothers and other Parents with HIV in the United States.

Date: March 28, 2024. Time: 10 a.m.–5 p.m., EDT. Place: Videoconference.

Agenda: To review and evaluate grant applications.

For Further Information Contact:
Seraphine Pitt Barnes, Ph.D., M.P.H.,
C.H.E.S., Scientific Review Officer,
National Center for HIV, Viral Hepatitis,
STD, and TB Prevention, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop H24–6,
Atlanta, Georgia 30329–4027.
Telephone: (770) 488–6115; Email:
SPittBarnes@cdc.gov.

The Director, Office of Strategic
Business Initiatives, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.

### Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2024–00214 Filed 1–8–24; 8:45 am]

BILLING CODE 4163-18-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Medicare & Medicaid Services

[Document Identifiers: CMS-10398 #43, #45, and #48]

Medicaid and Children's Health Insurance Program (CHIP) Generic Information Collection Activities: Proposed Collection; Comment Request

**AGENCY:** Centers for Medicare & Medicaid Services, Health and Human Services (HHS).

**ACTION:** Notice.